Company Overview

Update
Status:
Acquired by Sanofi Aventis
Founded:
2002
Headquarters:
Brisbane, CA
Funding:
$73M
Categories:
Health and Wellness, Biotechnology
Description:
BiPar Sciences is a pharmacological company developing PARP inhibitors as cancer therapies.

Detailed Description

Update

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.

BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture Partners, Asset Management Company, and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.

On April 15th, 2009, French drug maker Sanofi-Aventis S.A. announced it was acquiring BiPar Sciences for up to $500 million.

Current Team (4)

Update

Past Team (3)

Update

Products (1)

Update
  • Cb default image

    BSI-201

    BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and...

Investors (7)

Update

Offices/Locations (1)

Update
  • Headquarters

    1000 Marina Blvd.

    Suite 550

    Brisbane, CA 94005

    USA